What Are the Results of SLU-PP-332?

[AASraw]

A new research on SLU-PP-332 was published in The Journal of Pharmacology and Experimental Therapy in September 2023. It demonstrated that mice seemed to have run on a treadmill for several hours after took SLU-PP-332, and the following changes were observed:

• Increased fatty acid oxidation, and the body turned to burning fat (similar to the body using fatty acids when fasting or exercising).
• Enhanced mitochondrial respiration, and enhanced skeletal muscle oxidation capacity and endurance, increased mitochondrial content, and changes similar to those that occurred in aerobic training.
• Reduced glycogen and increased pyruvate in muscles.
• Increased resting energy expenditure.
• Mice with normal weight extended running time by 70% and running distance by 45%.
• Mice with normal weight increased energy consumption, increased muscle glucose absorption, and unchanged glucose tolerance.
• Mice with obesity improved glucose tolerance, improved fatty liver, reduced blood lipids, and reduced fat accumulation.
• After one month of medication, obese mice that ate the same food and did not exercise was 12% lighter than obese mice that did not take the drug.

SLU-PP-332 did not affect the mice’s appetite, nor did it lead them to exercise more. But it activated the metabolic pathways that respond to exercise, allowing the body to consume more energy and metabolize fat more quickly. Overall, SLU-PP-332 can improve fatty acid burning and reduce fat mass, making it potentially useful in the treatment of metabolic illnesses such as obesity and type 2 diabetes.